Furthest along
2 in Phase 1
Drugs
2
in active trials
Trials
3 active
3 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
In vivo CD19 CAR-T, mRNA in CD8-targeted lipid nanoparticles |
Phase 1 | 31 May 2027Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 May 2027 · Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Scleroderma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Dec 2027Phase 1 trial completes | |||
| Next date | 31 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Autoimmune Disease, Systemic Lupus Erythematosus and 1 more | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev